Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm, Prospective, Open-label, Exploratory Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer Patients After at Least Second-line Standard Treatment

NCT04227041 is registered in ClinicalTrials.gov with Qingdao Zhixin Health Technology Co., Ltd. as lead sponsor.

NCT NCT04227041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04227041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm, Prospective, Open-label, Exploratory Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer Patients After at Least Second-line Standard Treatment
Lead sponsor
Qingdao Zhixin Health Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 10, 2020
Completion date
January 10, 2023
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive colorectal cancer